Cargando…
Prediabetes in Colombia: Expert Consensus
The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universidad del Valle
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896726/ https://www.ncbi.nlm.nih.gov/pubmed/29662261 http://dx.doi.org/10.25100/cm.v43i4.3662 |
_version_ | 1783313868522520576 |
---|---|
author | López-Jaramillo, Patricio Calderón, Carlos Castillo, Jorge Escobar, Iván Darío Melgarejo, Enrique Parra, Gustavo Adolfo |
author_facet | López-Jaramillo, Patricio Calderón, Carlos Castillo, Jorge Escobar, Iván Darío Melgarejo, Enrique Parra, Gustavo Adolfo |
author_sort | López-Jaramillo, Patricio |
collection | PubMed |
description | The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our expert group recommends that educational programs emphasize a global approach to risk which includes a recognition of the importance of prediabetes and its evaluation along with and other risk factors such as a family history of DM2, overweight and obesity, dislipidemia and hypertension. Studies conducted in Colombia demonstrate the value of the FINDRIS questionnaire as a tool to identify subjects at risk of prediabetes and DM2, and we recommend that it should be systematic applied throughout the country as part of government policy. Prediabetes progresses to DM2 at an annual rate of 10%, but it has also been shown that prediabetes is an independent risk factor for cardiovascular outcomes. On this basis, the Committee recommends that once prediabetes is detected and diagnosed, immediate management of the disease begins through lifestyle changes, with follow up assessments performed at 3 and 6 months. If the patient does not respond with a weight loss of at least 5% and if the HbA1C values are not normalized, pharmacological management should be initiated with a metformin dose of 500 mg / day, increasing up to 1,500 - 1,700 mg / day, according to tolerance. |
format | Online Article Text |
id | pubmed-5896726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Universidad del Valle |
record_format | MEDLINE/PubMed |
spelling | pubmed-58967262018-04-16 Prediabetes in Colombia: Expert Consensus López-Jaramillo, Patricio Calderón, Carlos Castillo, Jorge Escobar, Iván Darío Melgarejo, Enrique Parra, Gustavo Adolfo Colomb Med (Cali) Article Review The prevalence of Prediabetes in Colombia is high, and despite being recognized and categorized in the main Medical Guidelines and included in the International Classification of Diseases in Colombia, knowledge and awareness of it is limited amongst healthcare professionals and in the community. Our expert group recommends that educational programs emphasize a global approach to risk which includes a recognition of the importance of prediabetes and its evaluation along with and other risk factors such as a family history of DM2, overweight and obesity, dislipidemia and hypertension. Studies conducted in Colombia demonstrate the value of the FINDRIS questionnaire as a tool to identify subjects at risk of prediabetes and DM2, and we recommend that it should be systematic applied throughout the country as part of government policy. Prediabetes progresses to DM2 at an annual rate of 10%, but it has also been shown that prediabetes is an independent risk factor for cardiovascular outcomes. On this basis, the Committee recommends that once prediabetes is detected and diagnosed, immediate management of the disease begins through lifestyle changes, with follow up assessments performed at 3 and 6 months. If the patient does not respond with a weight loss of at least 5% and if the HbA1C values are not normalized, pharmacological management should be initiated with a metformin dose of 500 mg / day, increasing up to 1,500 - 1,700 mg / day, according to tolerance. Universidad del Valle 2017-12-30 /pmc/articles/PMC5896726/ /pubmed/29662261 http://dx.doi.org/10.25100/cm.v43i4.3662 Text en Copyright © 2017 Universidad del Valle This article is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Article Review López-Jaramillo, Patricio Calderón, Carlos Castillo, Jorge Escobar, Iván Darío Melgarejo, Enrique Parra, Gustavo Adolfo Prediabetes in Colombia: Expert Consensus |
title | Prediabetes in Colombia: Expert Consensus |
title_full | Prediabetes in Colombia: Expert Consensus |
title_fullStr | Prediabetes in Colombia: Expert Consensus |
title_full_unstemmed | Prediabetes in Colombia: Expert Consensus |
title_short | Prediabetes in Colombia: Expert Consensus |
title_sort | prediabetes in colombia: expert consensus |
topic | Article Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896726/ https://www.ncbi.nlm.nih.gov/pubmed/29662261 http://dx.doi.org/10.25100/cm.v43i4.3662 |
work_keys_str_mv | AT lopezjaramillopatricio prediabetesincolombiaexpertconsensus AT calderoncarlos prediabetesincolombiaexpertconsensus AT castillojorge prediabetesincolombiaexpertconsensus AT escobarivandario prediabetesincolombiaexpertconsensus AT melgarejoenrique prediabetesincolombiaexpertconsensus AT parragustavoadolfo prediabetesincolombiaexpertconsensus |